following a full submission assessed under the orphan medicine process:
lenalidomide hard capsules (Revlimid®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).
In phase III, randomised studies, lenalidomide maintenance treatment improved progression-free survival in patients with newly diagnosed multiple myeloma who had undergone ASCT compared with placebo or observation. Median overall survival data were supportive of lenalidomide maintenance treatment.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- lenalidomide (Revlimid)
- SMC ID:
As monotherapy is indicated in multiple myeloma (MM) for the maintenance treatment of adult patients with newly diagnosed MM who have undergone autologous stem cell transplantation (ASCT).
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 12 October 2020